Zynex (NASDAQ:ZYXI) Posts Earnings Results, Beats Estimates By $0.01 EPS

Zynex (NASDAQ:ZYXI - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01, Briefing.com reports. The business had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The company's revenue was up .1% compared to the same quarter last year. During the same period last year, the company posted $0.10 EPS.

Zynex Stock Up 6.2 %

Shares of NASDAQ:ZYXI traded up $0.53 during midday trading on Friday, hitting $9.12. 264,450 shares of the stock were exchanged, compared to its average volume of 173,892. The company has a debt-to-equity ratio of 1.79, a quick ratio of 3.22 and a current ratio of 4.06. Zynex has a 52-week low of $7.04 and a 52-week high of $13.77. The business's fifty day simple moving average is $7.96 and its two-hundred day simple moving average is $9.23. The company has a market capitalization of $289.47 million, a PE ratio of 51.11 and a beta of 0.54.

Analysts Set New Price Targets

ZYXI has been the subject of several recent analyst reports. Royal Bank of Canada decreased their target price on Zynex from $12.00 to $11.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. HC Wainwright raised their target price on Zynex from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday.

Insider Buying and Selling

In other news, Director Joshua R. Disbrow acquired 7,000 shares of the business's stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the acquisition, the director now owns 72,000 shares in the company, valued at approximately $599,040. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Joshua R. Disbrow acquired 7,000 shares of the business's stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the acquisition, the director now owns 72,000 shares in the company, valued at approximately $599,040. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anna Lucsok sold 8,083 shares of the firm's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the transaction, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 52.13% of the stock is owned by corporate insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.